Trending

Johnson and Johnson

The top 5 pharma M&A deals of 2020

The top 5 pharma M&A deals of 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout

X

The top 5 pharma M&A deals of 2020

https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/

Nothing should stand in the way of coronavirus vaccine access, says J&J

Nothing should stand in the way of coronavirus vaccine access, says J&J

Janssen’s chief scientific officer and worldwide chairman Paul Stoffels has said he hopes the company’s coronavirus vaccine candidate

X

Nothing should stand in the way of coronavirus vaccine access, says J&J

https://pharmaphorum.com/news/nothing-should-stand-in-the-way-of-coronavirus-vaccine-access-says-jj/

Johnson & Johnson: Partnering to eliminate disease

Johnson & Johnson: Partnering to eliminate disease

J&J’s global head of external innovation communication on how partnerships are fuelling the company’s vision for a World

X

Johnson & Johnson: Partnering to eliminate disease

https://pharmaphorum.com/views-and-analysis/johnson-johnson-partnering-to-eliminate-disease/

Zytiga generics looming as US court nixes J&J patent

Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the

X

Zytiga generics looming as US court nixes J&J patent

https://pharmaphorum.com/news/zytiga-generics-looming-as-us-court-nixes-jj-patent/

J&J builds case for HIV vaccine ahead of pivotal trial readout

Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help

X

J&J builds case for HIV vaccine ahead of pivotal trial readout

https://pharmaphorum.com/news/jj-builds-case-hiv-vaccine/

J&J tops the pharma market cap charts – but for how long?

Data and analytics firm GlobalData has tracked the market cap and performance of the top 25 pharma companies

X

J&J tops the pharma market cap charts – but for how long?

https://pharmaphorum.com/views-and-analysis/jj-tops-pharma-market-cap-charts-long/

J&J seals $2.1bn deal on sale of major diabetes devices firm

J&J seals $2.1bn deal on sale of major diabetes devices firm

As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson &

X

J&J seals $2.1bn deal on sale of major diabetes devices firm

https://pharmaphorum.com/news/jj-deal-glucose-monitoring-system/

J&J offered $2.7 billion for sterilisation business by Fortive

Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.

X

J&J offered $2.7 billion for sterilisation business by Fortive

https://pharmaphorum.com/news/jnj-sterilisation-business-fortive/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com